130855-30-0

Basic information

• Product Name: PAROXETINE RELATED COMPOUND C (15 MG) ((+)-TRANS-PAROXETINE HYDROCHLORIDE)
• Synonyms: PAROXETINE RELATED COMPOUND C (15 MG) ((+)-TRANS-PAROXETINE HYDROCHLORIDE);(+)-trans-Paroxetine hydrochloride;Paroxetine Related CoMpound C;(3R,4S)-3-[(1,3-Benzodioxol-5-yloxy)Methyl]-4-(4-fluorophenyl)piperidine Hydrochloride;(3R-trans)-3-[(1,3-Benzodioxol-5-yloxy)Methyl]-4-(4-fluorophenyl)piperidine Hydrochloride;ent-Paroxetine Hydrochloride;(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)Methyl]-4-(4-fluorophenyl)piperidine hydrochloride (aka Paroxetine iMpurity D);Paroxetine HCl EP IMp D (USP RC C)
• CAS NO: 130855-30-0
• Molecular Formula: C19H21ClFNO3
• Molecular Weight: 365.8263432
• EINECS: 208-028-7
• Product Categories: Aromatics;Heterocycles;Impurities;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 130855-30-0.mol
• Article Data: 29

Chemical Properties

• Appearance: /
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Methanol (Slightly), Water (Slightly)
• Stability: Hygroscopic
• CAS DataBase Reference: PAROXETINE RELATED COMPOUND C (15 MG) ((+)-TRANS-PAROXETINE HYDROCHLORIDE)(CAS DataBase Reference)
• NIST Chemistry Reference: PAROXETINE RELATED COMPOUND C (15 MG) ((+)-TRANS-PAROXETINE HYDROCHLORIDE)(130855-30-0)
• EPA Substance Registry System: PAROXETINE RELATED COMPOUND C (15 MG) ((+)-TRANS-PAROXETINE HYDROCHLORIDE)(130855-30-0)

Safety Data

• Hazard Codes: Xi
• Statements: 41-62
• Safety Statements: 26-39
• Hazardous Substances Data: 130855-30-0(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 130855-30-0 differently. You can refer to the following data:
1. An enantiomeric impurity of Paroxetine (P205750).
2. ent-Paroxetine Hydrochloride (Paroxetine EP Impurity D; Paroxetine USP Related Compound C) is an enantiomeric impurity of Paroxetine (P205750).

Upstream product

• 61869-08-7 paroxetine 
• 246850-71-5 (3S,4R)-trans-1-benzyloxycarbonyl-4-(4-fluorophenyl)-3-[(3,4-methylenedioxyphenyl)oxymethyl]piperidine 
• 352-13-6 4-flourophenylmagnesium bromide 
• 1381968-84-8 C₂₀H₃₁NO₃Si 
• 349446-96-4 {(3S,4R)-4-(p-fluorophenyl)-3-(hydroxymethyl)-1-[1-(S)-phenylethyl]}piperidine 
• 533-31-3 Sesamol 
• 147-71-7 D-tartaric acid 
• 100332-09-0 4-(4-fluorophenyl)-3-hydroxymethyl-1-methyl-1,2,3,4-tetrahydropyridine 
• 105834-27-3 (-)-trans-1-Benzyl-4-(4-fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine Hydrochloride 
• 105834-28-4 (-)trans-1-benzyl-4-(4-fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine 

Relevant articles and documents

Total synthesis of (±)-paroxetine by diastereoconvergent cobalt-catalysed arylation

A total synthesis of paroxetine is reported, with a diastereoselective and diastereoconvergent cobalt-catalysed sp3-sp2 coupling reaction involving a 3-substituted 4-bromo-N-Boc-piperidine (Boc = tert-butoxycarbonyl) substrate as a key step. A 9:1 diastereoselectivity was obtained, while a control experiment involving a conformationally locked 3-substituted 4-bromo-tert-butyl cyclohexane ring proceeded with essentially complete stereoselectivity.

Stereodivergent α-allylation of linear aldehydes with dual iridium and amine catalysis

We describe the fully stereodivergent, dual catalytic α-allylation of linear aldehydes. The reaction proceeds via direct iridium-catalyzed substitution of racemic allylic alcohols with enamines generated in situ. The use of an Ir(P,olefin) complex and a diarylsilyl prolinol ether as catalysts in the presence of dimethylhydrogen phosphate as the promoter proved to be crucial for achieving high enantio- and diastereoselectivity (>99% ee, up to >20:1 dr). The utility of the method is demonstrated in a concise enantioselective synthesis of the antidepressant (-)-paroxetine.

SULFATED GALACTANS WITH ANTITHROMBOTIC ACTIVITY, PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING OR PROPHYLAXIS OF ARTERIAL OR VENOUS THROMBOSIS, METHOD OF EXTRACTION AND USE THEREOF

The present invention relates to low molecular weight sulfated galactans, obtained from algae, particularly genus Botryocladia, preferably species Botryocladia occidentallis, which have no effect on the factor XII activation of the clotting cascade, having antithrombotic heparinoid activity. The present invention also refers to a pharmaceutical composition comprising said sulfated galactans and the use thejreof, as heparin substitute, in the treatment or prophylaxis of arterial or venous thrombosis in humans and animals. Furthermore, the present invention provides a method of extraction of the said sulfated galactans.